BioXcel Therapeutics, Inc. (BTAI)

BioXcel Therapeutics' stock has experienced volatility over the past six months. The stock price ranged between $1.01 and $8.08 over the past 52 weeks, and as of early May 2026, it was trading around $1.21-$1.22, representing a decrease of approximately 23.8% since the beginning of 2026. In April 2026, BioXcel Therapeutics announced a virtual event to discuss the commercial launch plan for IGALMI in the at-home setting and issued warrants in a private equity financing deal. H.C. Wainwright maintained a "Buy" rating but cut its price target from $6 to $5 in April 2026, citing concerns over recent and expected equity dilution. In early April 2026, BioXcel Therapeutics announced the enrollment of the first patients in a U.S. Department of War-funded study of BXCL501 for the treatment of acute stress reactions. The FDA accepted a Supplemental New Drug Application (sNDA) for the use of IGALMI in the at-home setting in April 2026. In March 2026, the company reported its Fourth Quarter and Full-Year 2025 financial results as it prepared for potential IGALMI approval in the outpatient setting. The company's auditor has raised a "going concern" doubt, and a pattern of direct offerings and warrant issuances indicates persistent balance sheet stress. Shareholders have been substantially diluted in the past year, with a 66% increase in shares outstanding.

Information regarding specific demand seasonality for BioXcel Therapeutics' products and services is not explicitly available. Demand for its products like IGALMI would likely be driven by medical need and prescription rates rather than traditional seasonal consumer patterns. Factors such as disease prevalence, treatment guidelines, and market access would be more influential than seasonality.

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing AI and machine learning to discover and develop medicines in neuroscience and immuno-oncology. Their approach focuses on identifying new therapeutic indications for existing drugs. Their main commercial product is IGALMI, FDA-approved for acute agitation associated with schizophrenia or bipolar disorder in adults. The company's pipeline includes BXCL501 for agitation in Alzheimer's and other neuropsychiatric conditions, BXCL701 for aggressive prostate cancer, pancreatic cancer, and other solid and liquid tumors, and early-stage candidates BXCL502, BXCL503, and BXCL504 targeting dementia-related symptoms.

BioXcel Therapeutics, Inc. is headquartered in New Haven, Connecticut, USA. The company primarily serves the U.S. market and is exploring opportunities for global expansion.

BioXcel Therapeutics' reputation has been influenced by positive developments and financial concerns. The FDA acceptance of a Supplemental New Drug Application for IGALMI for at-home use and the enrollment of the first patients in a U.S. Department of War-funded study for BXCL501 in acute stress reactions are positive developments. Analyst consensus for the stock is generally "Hold" with some "Buy" ratings. Challenges include the company's auditor raising a "going concern" doubt, concerns over equity dilution, a significant stock decline, and reliance on external financing.

BioXcel Therapeutics, Inc. is owned by a mix of institutional shareholders, insiders, and retail investors. Vimal Mehta is the largest individual shareholder, owning 17.61 million shares, representing 65.05% of the company. BioXcel Holdings Inc. also holds a significant portion with 17.56 million shares (64.88%). Krishnan Nandabalan owns 17.09 million shares (63.14%). Major institutional shareholders include Millennium Management Llc, Vanguard Group Inc, Oaktree Capital Management Lp, Geode Capital Management, Llc, BlackRock, Inc., and State Street Corp. Mutual funds and ETFs hold 2.09% of shares outstanding, while other institutional investors hold 22.22%.